[1]王聪,张曦平,姚昶,等.仁术三黄方治疗乳腺癌术后内分泌治疗期气虚血瘀证临床疗效观察[J].西部中医药,2024,37(10):93-97.[doi:10.12174/j.issn.2096-9600.2024.10.21]
　WANG Cong,ZHANG Xiping,YAO Chang,et al.Clinical Observation of Renzhu Sanhuang Formula in the Treatment of Qi Deficiency and Blood Stasis Pattern of Postoperative Endocrine Treatment Period for Breast Cancer[J].Western Journal of Traditional Chinese Medicine,2024,37(10):93-97.[doi:10.12174/j.issn.2096-9600.2024.10.21]
点击复制

仁术三黄方治疗乳腺癌术后内分泌治疗期气虚血瘀证临床疗效观察
分享到：

《西部中医药》[ISSN:2096-9600/CN:62-1204/R]

卷:
37
期数:
2024年10期
页码:
93-97
栏目:
临床研究
出版日期:
2024-10-15

文章信息/Info

Title:
Clinical Observation of Renzhu Sanhuang Formula in the Treatment of Qi Deficiency and Blood Stasis Pattern of Postoperative Endocrine Treatment Period for Breast Cancer
作者:
王聪, 张曦平, 姚昶, 许岩磊, 倪婷, 张晓清
南京中医药大学附属医院，江苏 南京 210029
Author(s):
WANG Cong, ZHANG Xiping, YAO Chang, XU Yanlei, NI Ting, ZHANG Xiaoqing
Affiliated Hospital of Nanjing University of TCM, Nanjing 210029, China
关键词:
乳腺癌; 慢性氧化应激; 免疫功能; 仁术三黄方
Keywords:
breast cancer; chronic oxidative stress; immunological function; formula
分类号:
R271.19
DOI:
10.12174/j.issn.2096-9600.2024.10.21
文献标志码:
B
摘要:
目的观察仁术三黄方治疗乳腺癌术后内分泌治疗期气虚血瘀证的临床疗效。 方法将乳腺癌术后接受内分泌治疗的60例气虚血瘀证患者随机分为对照组和治疗组各30例。对照组予乳腺癌术后内分泌治疗，治疗组在对照组基础上予仁术三黄方中药口服。比较两组患者治疗前后应激症状评分、血清氧化应激指标［一氧化氮（nitric oxide，NO）、超氧化物歧化酶（superoxide dismutase，SOD）、总抗氧化能力（total antioxidant capacity，T-AOC）］、免疫功能指标［细胞免疫（CD4+、CD8+、CD4+/CD8+），体液免疫［免疫球蛋白M（immunoglobulin M，IgM）、IgA、IgG］及肿瘤相关指标［癌胚抗原（carcinoembryonic antigen，CEA）、糖类抗原153（carbohydrate antigen-153，CA153）、糖类抗原125（carbohydrate antigen-125，CA125）］变化情况，观察两组患者临床疗效。 结果治疗后对照组患者相关应激症状积分均升高（P＜0.05），治疗组均降低（P＜0.05）；治疗后对照组患者血清NO水平升高（P＜0.05），SOD、T-AOC水平降低（P＜0.05）；治疗组血清NO水平降低（P＜0.05），SOD、T-AOC水平升高（P＜0.05）。治疗后对照组患者细胞免疫相关指标CD4+、CD4+/CD8+表达均降低（P＜0.05），CD8+表达虽然升高，但差异无统计学意义（P＞0.05）；治疗组CD4+、CD4+/CD8+表达均升高（P＜0.05），CD8+表达虽然降低，但差异无统计学意义（P＞0.05）。治疗后两组患者体液免疫相关指标IgM、IgA、IgG表达均升高（P＜0.05），治疗组高于对照组（P＜0.05）。治疗后对照组患者CEA表达水平升高（P＜0.05），但CA153、CA125表达差异无统计学意义（P＞0.05）；治疗组CEA、CA153、CA125表达水平均降低（P＜0.05）。治疗组总有效率为100.00%（30/30），高于对照组的13%（4/30）（P＜0.05）。 结论仁术三黄方能改善乳腺癌术后内分泌治疗患者慢性氧化应激状态，提高患者免疫功能，降低癌症复发风险，改善患者气虚血瘀症状，疗效优于单纯内分泌治疗。
Abstract:
ObjectiveTo observe clinical effects of Renzhu Sanhuang formula in the treatment of Qi deficiency and blood stasis pattern of postoperative endocrine treatment period for breast cancer. MethodsSixty patients were randomized into the control group and the treatment group with 30 cases in each group. The control group accepted postoperative endocrine treatment for breast cancer, and the treatment group took Renzhu Sanhuang formula on the foundation of the therapy the control group received. To compare stress symptom score, the indicators of serum oxidative stress including NO, SOD and T-AOC, the indexes of immunological function such as cellular immunity (CD4+, CD8+ and CD4+/CD8+), and humoral immunity (IgM, IgA and IgG), as well as tumor-related indexes including CEA, CA153 and CA125 before and after the treatment between both groups, to observe clinical effects between both groups. ResultsAfter the treatment, the relevant stress symptom scores increased in the control group (P<0.05), while the socres decreased in the treatment group (P<0.05). After the treatment, the levels of serum NO went up in the control group (P<0.05), the levels of SOD and T-AOC decreased (P<0.05); the levels of serum NO reduced in the treatment group (P<0.05), the levels of SOD and T-AOC elevated (P<0.05). After treating, the expressions of cellular immunity-related indexes such as CD4+, and CD4+/CD8+ lowered in the control group (P<0.05), though the expressions of CD8+ rose, the difference had no statistical meaning (P>0.05); while the increased expressions of CD4+, and CD4+/CD8+ and the reduced expressions of CD8+ were found in the treatment, the difference had no statistical meaning (P>0.05). After the treatment, the expressions of humoral immunity (IgM, IgA and IgG) were elevated in the two groups (P<0.05), the treatment group was higher than the control group (P<0.05). After the treatment, tumor-related index CEA was highly expressed in the control group (P<0.05), the difference had no statistical meaning in the expressions of CA153 and CA125 (P>0.05), and the expressions of CAE, CA153 and CA125 were reduced in the treatment group (P<0.05). Total effective rate of the treatment group was 100.00% (30/30), higher than 13% (4/30) of the control group (P<0.05). ConclusionRenzhu Sanhuang formula could improve chronic oxidative stress in patients undergoing postopera-tive endocrine treatment after the surgery of breast cancer, enhance the patients' immunological function, and reduce recurrence risk of cancer, as well as improve the patients' symptom, and its effects are superior to these of only endocrine treatment.

相似文献/References:

[1]王斌,王艳杰,梁贵文,等.乳积方防治乳腺癌患者术后复发转移的临床研究*[J].西部中医药,2013,26(08):101.
　WANG Bin,WANG Yanjie,LIANG Guiwen,et al.Clinical Study on RuJiFang to Prevent Postoperative Recurrence and Metastasis of Breast Cancer[J].Western Journal of Traditional Chinese Medicine,2013,26(10):101.
[2]侯俊明,江静.疏肝解郁法联合化疗治疗乳腺癌临床疗效分析[J].西部中医药,2014,27(09):1.
[3]王丽,何丽娟,朱玉芹.循证护理对乳腺癌化疗患者自尊水平和应对方式的影响[J].西部中医药,2014,27(11):134.
[4]朱慧华.纽曼护理对乳腺癌手术患者心理健康和生活质量的影响[J].西部中医药,2014,27(12):105.
[5]张晓华,张晓岚△,梁玉荣,等.综合心理干预对乳腺癌化疗患者医学应对方式及生命质量的影响[J].西部中医药,2015,28(07):123.
[6]谷雨,华海清△.中医辨证分型与乳腺癌预后的相关性研究[J].西部中医药,2015,28(04):85.
[7]刘琛,吴黎雅,赵红佳,等.人参养荣汤干预乳腺癌新辅助化疗所致气血两虚证的临床研究[J].西部中医药,2011,24(11):3.
[8]李树建.扶正祛积汤联合CEF化疗方案治疗晚期乳腺癌40例临床研究[J].西部中医药,2013,26(09):1.
　LI Shujian.Clinical Study on FuZheng QuJiTang Combined with CEF Chemotherapy in Treating 40 Patients Suffering from Advanced Mammary Cancer[J].Western Journal of Traditional Chinese Medicine,2013,26(10):1.
[9]安妮,杨俊兰.消 疒徵祛积方联合化疗对晚期乳腺癌患者血清CEA、CA125、CA153和CA19-9含量及临床疗效的影响[J].西部中医药,2013,26(03):7.
　AN Ni,YANG Junlan.Effects of XiaoZhen QuJiFang and Chemotherapy on Clinical Efficacy and Contents of Serum CEA, CA125, CA153 and CA19-9 of Patients with Mammary Cancer at Advanced Stage[J].Western Journal of Traditional Chinese Medicine,2013,26(10):7.
[10]朱竹华,许敏菊,张汀荣,等.以家庭为中心的护理模式在完全植入式静脉输液港乳腺癌化疗患者中的应用[J].西部中医药,2016,29(03):114.
　ZHU Zhuhua,XU Minju,ZHANG Dingrong,et al.FCC Applying to Breast Cancer Patients Who Received Chemotherapy by TIVAP[J].Western Journal of Traditional Chinese Medicine,2016,29(10):114.

备注/Memo

备注/Memo:
王聪（1992—），男，在读博士研究生，主治中医师。研究方向：乳腺疾病的中医药诊治。国家自然科学基金（81804103）；江苏省中医院高峰学术人才培养项目（y2018rc11）；江苏省中医院培育项目（Y20031）。
更新日期/Last Update: 2024-10-15